Stoke Therapeutics Q1 Revenue Plummets 96% to $6.2M, Swings to $50M Net Loss
Summary
Stoke Therapeutics reported a significant financial downturn for Q1 2026, with revenue plummeting 96.1% year-over-year to $6.2 million, down from $158.6 million in Q1 2025. The company also swung to a substantial net loss of $50.0 million, or $(0.79) diluted EPS, a stark contrast to the net income of $112.9 million, or $1.90 diluted EPS, reported in the prior year period. This performance represents a material reversal from the positive financial trends highlighted in the company's 2025 10-K, which noted a reduction in net loss and increased revenue. The significant decline in revenue and shift to a considerable net loss are highly material for the company, potentially impacting its financial outlook and investor confidence despite ongoing clinical progress. Traders will be watching for further details on the drivers of this revenue decline and any updated guidance.
At the time of this announcement, STOK was trading at $30.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $8.51 to $40.22. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.